Expansion of TAVR into Low-Risk Patients and Who to Consider for SAVR

Kunal V. Patel, Wally Omar, Pedro Engel Gonzalez, Michael E. Jessen, Lynn Huffman, Dharam J. Kumbhani, Anthony A. Bavry

Research output: Contribution to journalReview articlepeer-review

12 Scopus citations


Transcatheter aortic valve replacement (TAVR) has revolutionized the treatment of severe aortic stenosis (AS) over the last decade. The results of the Placement of Aortic Transcatheter Valves (PARTNER) 3 and Evolut Low Risk trials demonstrated the safety and efficacy of TAVR in low-surgical-risk patients and led to the approval of TAVR for use across the risk spectrum. Heart teams around the world will now be faced with evaluating a deluge of younger, healthier patients with severe AS. Prior to the PARTNER 3 and Evolut Low Risk studies, this heterogenous patient population would have undergone surgical aortic valve replacement (SAVR). It is unlikely that TAVR will completely supplant SAVR for the treatment of severe AS in patients with a low surgical risk, as SAVR has excellent short- and long-term outcomes and years of durability data. In this review, we outline the critical role that SAVR will continue to play in the treatment of severe AS in the post-PARTNER 3/Evolut Low Risk era.

Original languageEnglish (US)
Pages (from-to)377-394
Number of pages18
JournalCardiology and Therapy
Issue number2
StatePublished - Dec 1 2020


  • Aortic stenosis
  • Low risk
  • SAVR
  • TAVR

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine


Dive into the research topics of 'Expansion of TAVR into Low-Risk Patients and Who to Consider for SAVR'. Together they form a unique fingerprint.

Cite this